Liposomal azithromycin in cotaneous leishmaniasis

Comparison of topical liposomal azithromycin plus azithromycin and azithromycin in in the treatment of cutaneous leishmaniasis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180425039414N1

Enrollment

Registered

2019-07-27

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis. L00-L08

Interventions

Intervention 1: Intervention group: Local topical liposomal erythromycin, which was coated every 12 hours on the surface of the surface, with an oral erythromycin capsule of 500 mg every 12 hours. Int

Eligibility

Sex/Gender

All

Age

1 Years to No maximum

Inclusion criteria

Inclusion criteria: New cases of cutaneous leishmaniasis 1-5 lesions with 3 cm and diameter more than 3 cm

Exclusion criteria

Exclusion criteria: More than 5 lesions Lesions on face, neck, joint and mucosal sites or sporotrichoid like lesions Lung surface size is more than 5 Square centimeters The patient is pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Leishmaniasis. Timepoint: 6 weeks, 12 weeks and 6 months after treatment. Method of measurement: Digital photography.	—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtousa Hakamifard

Esfahan University of Medical Sciences

a.hakamifard@med.mui.ac.ir+98 31 3668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026